NovoHeart

Novoheart is a pioneering biotechnology firm that has developed the world's first human heart-in-a-jar and a suite of bioengineered human heart constructs for preclinical research. Its proprietary mini-Heart Platform leverages human pluripotent stem cells to create functional cardiac tissues for modeling diseases and assessing drug toxicity and efficacy, aiming to reduce costs and time in drug development. The company operates primarily as a platform and services provider, supporting pharmaceutical partners in advancing candidates, with its technology having contributed to multiple Investigational New Drug (IND) applications. While likely pre-revenue or in early revenue stages, Novoheart is positioned at the intersection of regenerative medicine and cardiovascular research, addressing a critical need for more predictive human-relevant models.

The mini-Heart Platform: a suite of bioengineered human heart constructs (hvCMs, hvCTS, hvCAS) derived from human pluripotent stem cells for disease modeling and drug screening. Includes the world's first human heart-in-a-jar.

Novoheart competes in the advanced in vitro models (organ-on-a-chip) and stem cell-based assay market. Key competitors include companies like Valo Health, HeartBeat.bio, and CN Bio, as well as academic spinoffs developing cardiac microtissues. Its differentiation lies in its specific focus on 3D functional contractility and arrhythmia assays for the human heart.